AstraZeneca: wins Japan approval for hyperkalaemia drug

(CercleFinance.com) - AstraZeneca's Lokelma has been approved in Japan for the treatment of patients with high levels of potassium in the blood, the Anglo-Swedish pharmaceuticals group said on Thursday.


The approval comes as over 300,000 patients in Japan currently suffer from hyperkalaemia, usually as a result of chronic kidney disease.

Hyperkalaemia is considered as a life threatening condition because it can cause severe side effects, such as cardiac arrest.

Lokelma is a non-resin potassium binder, when traditional resin-based binders are often associated with poor tolerability.

Lokelma is now approved for the treatment of hyperkalaemia in the US, EU, Canada, China, and Japan, AstraZeneca said.

Copyright (c) 2020 CercleFinance.com. All rights reserved.